Literature DB >> 3362855

Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit.

S J Tzartos1, A Kokla, S L Walgrave, B M Conti-Tronconi.   

Abstract

The majority of antibodies to the acetylcholine receptor (AcChoR), both in the human disease myasthenia gravis and in its experimental models, are directed against an extracellular area of the AcChoR alpha subunit called the main immunogenic region (MIR). We have studied the binding of anti-AcChoR monoclonal antibodies (mAbs) to 26 synthetic peptides corresponding to the hydrophilic parts of the human AcChoR alpha subunit. The binding sites for eight anti-MIR mAbs and for eight anti-alpha-subunit, non-anti-MIR mAbs were localized. Anti-MIR mAbs bound to one peptide corresponding to residues 63-80 of the human alpha subunit. A second panel of peptides corresponding to the various parts of the alpha-subunit segment 63-80 was synthesized. Anti-MIR antibodies bound to a peptide that contained the alpha-subunit sequence 67-76. Thus, a main constituent loop of the MIR is localized between residues 67 and 76 of the alpha subunit.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3362855      PMCID: PMC280110          DOI: 10.1073/pnas.85.9.2899

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Autoimmune response to acetylcholine receptor.

Authors:  J Patrick; J Lindstrom
Journal:  Science       Date:  1973-05-25       Impact factor: 47.728

2.  Monoclonal antibodies as probes of acetylcholine receptor structure. 2. Binding to native receptor.

Authors:  B Conti-Tronconi; S Tzartos; J Lindstrom
Journal:  Biochemistry       Date:  1981-04-14       Impact factor: 3.162

3.  Production and assay of antibodies to acetylcholine receptors.

Authors:  J Lindstrom; B Einarson; S Tzartos
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  A gas-liquid solid phase peptide and protein sequenator.

Authors:  R M Hewick; M W Hunkapiller; L E Hood; W J Dreyer
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

5.  Acetylcholine receptor: complex of homologous subunits.

Authors:  M A Raftery; M W Hunkapiller; C D Strader; L E Hood
Journal:  Science       Date:  1980-06-27       Impact factor: 47.728

6.  Mapping of surface structures of electrophorus acetylcholine receptor using monoclonal antibodies.

Authors:  S J Tzartos; D E Rand; B L Einarson; J M Lindstrom
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

7.  Mammalian muscle acetylcholine receptor: a supramolecular structure formed by four related proteins.

Authors:  B M Conti-Tronconi; C M Gotti; M W Hunkapiller; M A Raftery
Journal:  Science       Date:  1982-12-17       Impact factor: 47.728

8.  Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies.

Authors:  S J Tzartos; M E Seybold; J M Lindstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

9.  Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia.

Authors:  D P Richman; C M Gomez; P W Berman; S A Burres; F W Fitch; B G Arnason
Journal:  Nature       Date:  1980-08-14       Impact factor: 49.962

10.  Conformation of cytoplasmic segments of acetylcholine receptor alpha- and beta-subunits probed by monoclonal antibodies: sensitivity of the antibody competition approach.

Authors:  A A Kordossi; S J Tzartos
Journal:  EMBO J       Date:  1987-06       Impact factor: 11.598

View more
  44 in total

1.  Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide.

Authors:  N Venkatesh; S H Im; M Balass; S Fuchs; E Katchalski-Katzir
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients.

Authors:  S J Tzartos; M Remoundos
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

3.  A selective role for MRF4 in innervated adult skeletal muscle: Na(V) 1.4 Na+ channel expression is reduced in MRF4-null mice.

Authors:  Amy L Thompson; Gregory Filatov; Connie Chen; Isaac Porter; Yingjie Li; Mark M Rich; Susan D Kraner
Journal:  Gene Expr       Date:  2005

4.  Inhibition mechanism of the acetylcholine receptor by alpha-neurotoxins as revealed by normal-mode dynamics.

Authors:  Abraham O Samson; Michael Levitt
Journal:  Biochemistry       Date:  2008-03-08       Impact factor: 3.162

Review 5.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 6.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

Review 7.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

Review 8.  Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine.

Authors:  John A Dani
Journal:  Int Rev Neurobiol       Date:  2015-08-21       Impact factor: 3.230

9.  Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis.

Authors:  S J Tzartos; E Morel; A Efthimiadis; A F Bustarret; J D'Anglejan; A A Drosos; H A Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

10.  Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy.

Authors:  L X Fu; Y Magnusson; C H Bergh; J A Liljeqvist; F Waagstein; A Hjalmarson; J Hoebeke
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.